

**EXHIBIT A**

---

**GRACEWAY PHARMACEUTICALS, LLC, et al., CASE NO. 11-13036  
COPY OF THE RETENTION ORDER AUTHORIZING  
EMPLOYMENT OF THE APPLICANT**

---

**IN THE UNITED STATES BANKRUPTCY COURT  
FOR THE DISTRICT OF DELAWARE**

In re: )  
 ) Chapter 11  
**Graceway Pharmaceuticals, LLC, et al.**<sup>1</sup> ) Case No. 11-13036 (PJW)  
 ) (Jointly Administered)  
Debtors. )

**RE: Docket No. 164**

**ORDER AUTHORIZING RETENTION OF  
FTI CONSULTING, INC. AS FINANCIAL ADVISOR  
FOR THE OFFICIAL COMMITTEE OF UNSECURED CREDITORS**

Upon the application (the "Application")<sup>2</sup> of the Official Committee of Unsecured Creditors (the "Committee") of the above-captioned debtors and debtors in possession (collectively, the "Debtors"), for an order pursuant to section 1103 of chapter 11 of title 11 of the United States Code (the "Bankruptcy Code"), authorizing them to retain FTI Consulting, Inc., together with its wholly owned subsidiaries and employees, and those agents and independent contractors who hereinafter file appropriate declarations consistent with section 1103(b) of the Bankruptcy Code (collectively, "FTI"), as financial advisor; and upon the Affidavits of Samuel Star in support of the Application; and due and adequate notice of the Application having been given; and it appearing that no other notice need be given; and it appearing that FTI is not representing any adverse interests in connection with this case; and it appearing that the relief requested in the Application is in the best interest of the Committee; after due deliberation and sufficient cause appearing therefore, it is hereby

ORDERED that the Application be, and it hereby is, granted, as set forth herein; and it is

<sup>1</sup>The Debtors in these cases, along with the last four digits of each Debtor's federal tax identification number, are: Graceway Pharma Holding Corp., a Delaware corporation (9175); Graceway Holdings, LLC, a Delaware limited liability company (2502); Graceway Pharmaceuticals, LLC, a Delaware limited liability company (5385); Chester Valley Holdings, LLC, a Delaware limited liability company (9457); Chester Valley Pharmaceuticals, LLC, a Delaware limited liability company (3713); Graceway Canada Holdings, Inc., a Delaware corporation (6663); and Graceway International, Inc., a Delaware corporation (2399). The mailing address for Graceway Pharmaceuticals, LLC is 340 Martin Luther King Jr. Blvd., Suite 500, Bristol, TN 37620 (Attn: John Bellamy)

<sup>2</sup>Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Application.

further

ORDERED that the capitalized terms not defined herein shall have the meanings ascribed to them in the Application; and it is further

ORDERED that in accordance with sections 328(a) and 1103 of the Bankruptcy Code, Bankruptcy Rule 2014 and Rule 2014-1 of the Local Rules, the Committee is authorized to employ and retain FTI as of October 13, 2011 as their financial advisor on the terms set forth in the Application and as set forth in the affidavits of Samuel Star dated October 27, 2011 and November ~~17~~<sup>19</sup> 2011; and it is further

ORDERED that FTI shall be compensated and reimbursed for actual and necessary expenses upon the filing and approval of interim and final applications in accordance with the procedures set forth in sections 330 and 331 of the Bankruptcy Code and such Bankruptcy Rules and Local Rules of this Court, as may then be applicable, from time to time, and such applicable orders entered by this Court in respect of compensation of professionals.

ORDERED that FTI is entitled to reimbursement of actual and necessary expenses, including any reasonable legal fees incurred for FTI's defense of its retention and fee applications in this matter, subject to Court approval, provided that FTI shall attach to its fee applications those invoices of its counsel for which it seeks to be reimbursed, which invoices shall include the information required by the Bankruptcy Code and such Bankruptcy Rules and Local Rules of this Court, as may then be applicable from time to time, and such applicable orders entered by this Court in respect of compensation of professionals.

ORDERED that the following indemnification provisions are hereby approved:

a. subject to the provisions of subparagraphs (b) and (c) below, the Debtors are authorized to indemnify and hold harmless, and shall indemnify and hold harmless, FTI for any claims, liabilities, costs or expenses (including the reasonable fees and expenses

of its attorneys) arising from, related to, or in connection with any of the Debtors having furnished to FTI any false, inaccurate or misleading documents, reports, information (financial or otherwise), records, projections, books of record or financial statements, in each case, that FTI in turn distributes to or shares with the Committee or upon which FTI relied in providing advice to the Committee in connection with these Chapter 11 cases; and in furtherance of the foregoing the Debtors shall promptly pay reasonable expenses (including the reasonable fees and expenses of its attorneys) incurred by FTI in defending, participating in, or settling any action, proceeding or investigation in which FTI is a party or is threatened to be made a party or otherwise is participating in by reason of the engagement authorized herein, upon submission of invoices therefore, whether in advance of the final disposition of such action, proceeding, or investigation or otherwise, provided that FTI undertakes to repay any and all such amounts so advanced if it shall ultimately be determined that FTI is not entitled to be indemnified therefore pursuant to the terms hereof; and

b. the Debtors shall have no obligation to indemnify or to hold FTI harmless for any such claim, liability, cost or expense that is either (i) judicially determined (the determination having become final) to have arisen primarily from FTI's bad faith, gross negligence or willful misconduct; or (ii) settled prior to a judicial determination as to FTI's bad faith, gross negligence or willful misconduct, but determined by this Court, after notice and a hearing pursuant to subparagraph (c) infra, to be a claim, liability, cost or expense for which FTI is not entitled to receive indemnity or to be held harmless under the terms of the Application as modified by this Order; and

c. if, before the earlier of (i) the entry of an order confirming a chapter 11 plan in these cases (that order having become a final order no longer subject to appeal), and (ii) the entry of an order closing these chapter 11 cases, FTI believes that it is entitled to the payment of any amounts by the Debtors on account of the Debtors' indemnification and hold harmless obligations, including, without limitation, the advancement of defense costs, FTI must file an application therefore in this Court, and the Debtors may not pay any such amounts to FTI before the entry of an order by this Court approving the

payment. This subparagraph (c) is intended only to specify the period of time under which the Court shall have jurisdiction over any request for fees and expenses by FTI for said indemnification and hold harmless, and not as a provision limiting the duration of the Debtors' obligation to indemnify and hold FTI harmless; and it is further

ORDERED that this court shall retain jurisdiction with respect to all matters arising or related to the implementation of this order.

Dated: November 7, 2011

  
HONORABLE PETER J. WALSH

## EXHIBIT B

**GRACEWAY PHARMACEUTICALS, LLC, et al., CASE NO. 11-13036  
DETAILED PROFESSIONAL ACTIVITY BY HOURS AND FEES BY PROJECT CATEGORY  
FOR THE PERIOD NOVEMBER 1, 2011 THROUGH NOVEMBER 30, 2011**

### *Analysis of Claims/Liabilities Subject to Compromise*

<b>Professional</b>	<b>Date</b>	<b>Hours</b>	<b>Activity</b>	<b>Rate</b>	<b>Fees</b>
Greenberg, M.	01-Nov-11	1.3	Review 1st lien credit agreement, security agreement and guaranty agreement.	\$745	\$968.50
Swetz, M.	03-Nov-11	3.0	Review of Mezzanine credit agreement.	\$315	\$945.00
Greenberg, M.	04-Nov-11	0.6	Review Mezzanine loan agreement.	\$745	\$447.00
Star, S.	09-Nov-11	0.2	Review 1st lien lender claims.	\$895	\$179.00
Swetz, M.	10-Nov-11	0.9	Review cure costs estimated by Debtors.	\$315	\$283.50
Greenberg, M.	15-Nov-11	0.8	Review assigned contracts and corresponding cure costs.	\$745	\$596.00
<b>Subtotal</b>		<b>6.8</b>			<b>\$3,419.00</b>

### *Analysis of SOFAs & SOALs*

<b>Professional</b>	<b>Date</b>	<b>Hours</b>	<b>Activity</b>	<b>Rate</b>	<b>Fees</b>
Greenberg, M.	01-Nov-11	1.4	Review SOALs and SOFAs.	\$745	\$1,043.00
Swetz, M.	01-Nov-11	3.7	Review and summarize SOFAs and SOALs for each debtor entity.	\$315	\$1,165.50
Greenberg, M.	03-Nov-11	1.8	Review SOFAs and SOALs.	\$745	\$1,341.00
Greenberg, M.	04-Nov-11	1.7	Review SOFAs and SOALs.	\$745	\$1,266.50
Swetz, M.	04-Nov-11	1.9	Analyze SOFAs and SOALs.	\$315	\$598.50
Swetz, M.	05-Nov-11	1.6	Analyze SOFAs and SOALs and prepare summary schedules.	\$315	\$504.00
Greenberg, M.	08-Nov-11	0.5	Prepare UCC report regarding SOFAs/SOALs and potential preference payments.	\$745	\$372.50
Swetz, M.	08-Nov-11	2.5	Prepare SOFA / SOAL analysis for the purposes of UCC presentation.	\$315	\$787.50
Greenberg, M.	09-Nov-11	1.7	Prepare UCC report regarding SOALs and potential preference payments.	\$745	\$1,266.50
Swetz, M.	10-Nov-11	0.5	Develop questions for Debtors regarding SOFAs and SOALs.	\$315	\$157.50
Greenberg, M.	10-Nov-11	1.8	Prepare UCC report regarding SOALs and potential preference payments.	\$745	\$1,341.00
Swetz, M.	10-Nov-11	3.4	Prepare UCC presentation summarizing SOFAs and SOALs.	\$315	\$1,071.00
<b>Subtotal</b>		<b>22.5</b>			<b>\$10,914.50</b>

### *Asset Sales*

<b>Professional</b>	<b>Date</b>	<b>Hours</b>	<b>Activity</b>	<b>Rate</b>	<b>Fees</b>
---------------------	-------------	--------------	-----------------	-------------	-------------

**EXHIBIT B**

---

**GRACEWAY PHARMACEUTICALS, LLC, et al., CASE NO. 11-13036  
DETAILED PROFESSIONAL ACTIVITY BY HOURS AND FEES BY PROJECT CATEGORY  
FOR THE PERIOD NOVEMBER 1, 2011 THROUGH NOVEMBER 30, 2011**

---

*Asset Sales*

<b>Professional</b>	<b>Date</b>	<b>Hours</b>	<b>Activity</b>	<b>Rate</b>	<b>Fees</b>
Greenberg, M.	02-Nov-11	0.9	Review asset purchase agreement.	\$745	\$670.50
Greenberg, M.	03-Nov-11	2.0	Review data room documents pertaining to asset sale.	\$745	\$1,490.00
Greenberg, M.	04-Nov-11	0.3	Review data room contents pertaining to asset sale.	\$745	\$223.50
Greenberg, M.	04-Nov-11	0.3	Review PwC's summary of potential tax consequences associated with the asset sale.	\$745	\$223.50
Star, S.	09-Nov-11	0.6	Review draft objection to sale motion.	\$895	\$537.00
Greenberg, M.	09-Nov-11	1.2	Review counsel's draft sale objection and prepare comments and edits.	\$745	\$894.00
Star, S.	10-Nov-11	0.2	Review APA overbid provisions.	\$895	\$179.00
Greenberg, M.	10-Nov-11	0.4	Review bidding procedures and sale motion.	\$745	\$298.00
Greenberg, M.	10-Nov-11	1.0	Review letters of interest from potential asset sale bidders.	\$745	\$745.00
Greenberg, M.	11-Nov-11	0.3	Review draft objections to the sale motion and Canada value motion prepared by counsel.	\$745	\$223.50
Swetz, M.	11-Nov-11	0.4	Review of bidding procedures and APA.	\$315	\$126.00
Star, S.	11-Nov-11	0.6	Review draft sale motion objection.	\$895	\$537.00
Greenberg, M.	11-Nov-11	1.0	Review data room documents related to the asset sale.	\$745	\$745.00
Star, S.	12-Nov-11	0.9	Review alternate bid for assets.	\$895	\$805.50
Star, S.	14-Nov-11	0.1	Review revised sales motion objection.	\$895	\$89.50
Swetz, M.	14-Nov-11	0.4	Review asset sale objection.	\$315	\$126.00
Star, S.	14-Nov-11	0.5	Review alternative bids.	\$895	\$447.50
Joffe, S.	14-Nov-11	0.6	Review tax impact of purchase price allocation in 363 sale.	\$895	\$537.00
Swetz, M.	14-Nov-11	0.8	Review alternate bid and analyze differences from Stalking Horse bid with regard to cure costs.	\$315	\$252.00
Star, S.	14-Nov-11	0.9	Review documents in preparation for auction.	\$895	\$805.50
Greenberg, M.	14-Nov-11	2.9	Review alternate bids.	\$745	\$2,160.50
Greenberg, M.	15-Nov-11	0.6	Review bidding procedures order and bidding procedures.	\$745	\$447.00
Greenberg, M.	15-Nov-11	0.9	Review alternate asset purchase agreement.	\$745	\$670.50
Greenberg, M.	16-Nov-11	0.6	Review bidding procedures order and bidding procedures.	\$745	\$447.00
Swetz, M.	16-Nov-11	2.9	Analyze the APAs and create chart outlining differences.	\$315	\$913.50
Greenberg, M.	17-Nov-11	2.8	Review alternate asset purchase agreements.	\$745	\$2,086.00
Greenberg, M.	17-Nov-11	4.7	Participate in sale auction.	\$745	\$3,501.50

## EXHIBIT B

---

**GRACEWAY PHARMACEUTICALS, LLC, et al., CASE NO. 11-13036  
DETAILED PROFESSIONAL ACTIVITY BY HOURS AND FEES BY PROJECT CATEGORY  
FOR THE PERIOD NOVEMBER 1, 2011 THROUGH NOVEMBER 30, 2011**

---

### *Asset Sales*

<b>Professional</b>	<b>Date</b>	<b>Hours</b>	<b>Activity</b>	<b>Rate</b>	<b>Fees</b>
Swetz, M.	17-Nov-11	4.7	Participate in sale auction.	\$315	\$1,480.50
<b>Subtotal</b>		<b>33.5</b>			<b>\$21,661.50</b>

### *Cash & Liquidity Analysis*

<b>Professional</b>	<b>Date</b>	<b>Hours</b>	<b>Activity</b>	<b>Rate</b>	<b>Fees</b>
Greenberg, M.	03-Nov-11	0.3	Review revised DIP budget.	\$745	\$223.50
Meakin, N.	03-Nov-11	0.4	Review revised DIP budget.	\$870	\$348.00
Meakin, N.	03-Nov-11	0.5	Review UCC cash flow summary prepared by FTI.	\$870	\$435.00
Greenberg, M.	03-Nov-11	0.8	Analyze weekly cash variance report.	\$745	\$596.00
Greenberg, M.	03-Nov-11	0.8	Prepare cash flow summary for UCC.	\$745	\$596.00
Greenberg, M.	05-Nov-11	0.4	Review revised DIP budget.	\$745	\$298.00
Greenberg, M.	08-Nov-11	1.4	Review final cash collateral order and corresponding revised DIP budget.	\$745	\$1,043.00
Swetz, M.	08-Nov-11	2.3	Analyze revised DIP budget, and develop comparison to original DIP budget.	\$315	\$724.50
Greenberg, M.	11-Nov-11	0.3	Review final cash collateral order.	\$745	\$223.50
<b>Subtotal</b>		<b>7.2</b>			<b>\$4,487.50</b>

### *Firm Retention*

<b>Professional</b>	<b>Date</b>	<b>Hours</b>	<b>Activity</b>	<b>Rate</b>	<b>Fees</b>
Swetz, M.	01-Nov-11	3.2	Analyze relationship disclosure for supplemental retention documents.	\$315	\$1,008.00
Star, S.	02-Nov-11	0.2	Review supplemental affidavit.	\$895	\$179.00
Hellmund-Mora, M.	02-Nov-11	0.3	Review supplemental affidavit.	\$250	\$75.00
Swetz, M.	02-Nov-11	1.4	Prepare supplemental affidavit.	\$315	\$441.00
Swetz, M.	02-Nov-11	1.7	Finalize relationship disclosure and create exhibits to supplemental affidavit.	\$315	\$535.50
Star, S.	03-Nov-11	0.6	Review revised retention papers.	\$895	\$537.00
Hellmund-Mora, M.	03-Nov-11	0.6	Analyze relationship disclosure for supplemental retention documents.	\$250	\$150.00
Swetz, M.	03-Nov-11	0.8	Review of Trustee concerns regarding indemnification provision.	\$315	\$252.00



**EXHIBIT B**

---

**GRACEWAY PHARMACEUTICALS, LLC, et al., CASE NO. 11-13036  
DETAILED PROFESSIONAL ACTIVITY BY HOURS AND FEES BY PROJECT CATEGORY  
FOR THE PERIOD NOVEMBER 1, 2011 THROUGH NOVEMBER 30, 2011**

---

***Firm Retention***

<b>Professional</b>	<b>Date</b>	<b>Hours</b>	<b>Activity</b>	<b>Rate</b>	<b>Fees</b>
Star, S.	04-Nov-11	0.8	Draft revisions to retention papers.	\$895	\$716.00
Hellmund-Mora, M.	04-Nov-11	0.9	Analyze relationship disclosure for supplemental retention documents.	\$250	\$225.00
Star, S.	04-Nov-11	1.3	Gather information needed to respond to UST requests.	\$895	\$1,163.50
Swetz, M.	04-Nov-11	1.5	Review and revise supplemental affidavit.	\$315	\$472.50
Hellmund-Mora, M.	21-Nov-11	0.6	Analyze relationship disclosure for supplemental retention documents.	\$250	\$150.00
Swetz, M.	21-Nov-11	2.5	Review relationship disclosure results for supplemental retention documents.	\$315	\$787.50
Hellmund-Mora, M.	22-Nov-11	0.5	Analyze relationship disclosure for supplemental retention documents.	\$250	\$125.00
Greenberg, M.	30-Nov-11	0.3	Prepare second supplemental affidavit.	\$745	\$223.50
<b>Subtotal</b>		<b>17.2</b>			<b>\$7,040.50</b>

***General Meetings with Committee & Committee Counsel***

<b>Professional</b>	<b>Date</b>	<b>Hours</b>	<b>Activity</b>	<b>Rate</b>	<b>Fees</b>
Greenberg, M.	01-Nov-11	0.2	Correspondence with counsel regarding Canada allocation motion.	\$745	\$149.00
Star, S.	01-Nov-11	0.4	Discussions with counsel regarding response to allocation motion.	\$895	\$358.00
Star, S.	01-Nov-11	0.4	Conference call with counsel regarding settlement outline.	\$895	\$358.00
Greenberg, M.	01-Nov-11	0.5	Discussion with counsel regarding settlement terms and Graceway Canada value.	\$745	\$372.50
Greenberg, M.	02-Nov-11	0.3	Correspondence with counsel regarding upcoming Court hearings.	\$745	\$223.50
Star, S.	02-Nov-11	0.5	Meet with counsel regarding allocation motion.	\$895	\$447.50
Star, S.	02-Nov-11	1.4	Discussion with counsel regarding retention papers.	\$895	\$1,253.00
Meakin, N.	03-Nov-11	0.5	Conference call with Committee regarding pending motions, settlement discussions and cash position.	\$870	\$435.00
Star, S.	03-Nov-11	0.5	Conference call with Committee regarding pending motions, settlement discussions and cash position.	\$895	\$447.50
Greenberg, M.	03-Nov-11	0.5	Conference call with Committee regarding pending motions, settlement discussions and cash position.	\$745	\$372.50
Star, S.	03-Nov-11	1.5	Discussion with counsel regarding retention papers.	\$895	\$1,342.50
Star, S.	04-Nov-11	0.4	Discussions with counsel regarding Canada issues.	\$895	\$358.00

**EXHIBIT B**

---

**GRACEWAY PHARMACEUTICALS, LLC, et al., CASE NO. 11-13036  
DETAILED PROFESSIONAL ACTIVITY BY HOURS AND FEES BY PROJECT CATEGORY  
FOR THE PERIOD NOVEMBER 1, 2011 THROUGH NOVEMBER 30, 2011**

---

***General Meetings with Committee & Committee Counsel***

<b>Professional</b>	<b>Date</b>	<b>Hours</b>	<b>Activity</b>	<b>Rate</b>	<b>Fees</b>
Greenberg, M.	04-Nov-11	0.4	Discussion with counsel regarding potential retention of Canadian counsel.	\$745	\$298.00
Star, S.	04-Nov-11	1.1	Discussions with counsel regarding revisions to retention papers.	\$895	\$984.50
Greenberg, M.	06-Nov-11	0.1	Correspondence with counsel regarding mezzanine credit agreement and guaranty claim.	\$745	\$74.50
Meakin, N.	07-Nov-11	0.5	Call with counsel and Stikeman Elliott regarding retention of Canadian counsel.	\$870	\$435.00
Star, S.	07-Nov-11	0.6	Discussions with counsel regarding potential settlement.	\$895	\$537.00
Star, S.	08-Nov-11	0.3	Discussions with counsel regarding settlement counter.	\$895	\$268.50
Greenberg, M.	08-Nov-11	0.3	Discussion with counsel regarding terms of final cash collateral order.	\$745	\$223.50
Swetz, M.	08-Nov-11	0.3	Call with counsel regarding settlement with first liens.	\$315	\$94.50
Greenberg, M.	08-Nov-11	0.5	Discussion with counsel regarding Canada value and settlement negotiations.	\$745	\$372.50
Meakin, N.	08-Nov-11	1.0	Calls with counsel regarding valuation, settlement negotiations and the cash collateral order.	\$870	\$870.00
Greenberg, M.	09-Nov-11	0.4	Correspondence with counsel regarding sale objection.	\$745	\$298.00
Greenberg, M.	09-Nov-11	0.4	Discussion with counsel regarding Canada asset value.	\$745	\$298.00
Star, S.	09-Nov-11	0.6	Discussions with counsel regarding draft objection to sale motion.	\$895	\$537.00
Meakin, N.	09-Nov-11	1.0	Calls with counsel regarding valuation and settlement negotiations.	\$870	\$870.00
Swetz, M.	10-Nov-11	0.4	Call with counsel regarding the value of Canada and potential settlement.	\$315	\$126.00
Star, S.	10-Nov-11	0.5	Discussions with counsel regarding settlement offer.	\$895	\$447.50
Greenberg, M.	10-Nov-11	0.7	Participate in call with UCC regarding settlement negotiations, Canada value and SOFAs/SOALs.	\$745	\$521.50
Greenberg, M.	10-Nov-11	0.9	Correspondence with counsel regarding settlement negotiations, Canada value and bidding procedures.	\$745	\$670.50
Meakin, N.	10-Nov-11	1.0	Prepare for and participate in call with UCC regarding settlement negotiations, valuation and SOFA/SOAL.	\$870	\$870.00
Star, S.	11-Nov-11	0.4	Conference call with counsel regarding Committee counter proposal.	\$895	\$358.00
Star, S.	11-Nov-11	0.5	Discussions with counsel regarding sale motion objection.	\$895	\$447.50
Greenberg, M.	11-Nov-11	0.6	Discussion with counsel regarding Canada value and upcoming hearings.	\$745	\$447.00
Meakin, N.	11-Nov-11	1.0	Calls with counsel regarding valuation and settlement negotiations.	\$870	\$870.00

**EXHIBIT B**

---

**GRACEWAY PHARMACEUTICALS, LLC, et al., CASE NO. 11-13036  
DETAILED PROFESSIONAL ACTIVITY BY HOURS AND FEES BY PROJECT CATEGORY  
FOR THE PERIOD NOVEMBER 1, 2011 THROUGH NOVEMBER 30, 2011**

---

***General Meetings with Committee & Committee Counsel***

<b>Professional</b>	<b>Date</b>	<b>Hours</b>	<b>Activity</b>	<b>Rate</b>	<b>Fees</b>
Greenberg, M.	11-Nov-11	1.0	Correspondence with counsel regarding claim cure amounts and Canada equity value.	\$745	\$745.00
Swetz, M.	12-Nov-11	1.4	Call with counsel regarding settlement discussions and objection drafts.	\$315	\$441.00
Swetz, M.	14-Nov-11	0.2	Participate in call with counsel regarding negotiations with 1st lien lenders.	\$315	\$63.00
Greenberg, M.	14-Nov-11	0.4	Participate on call with counsel to discuss valuation motion and sale motion objections.	\$745	\$298.00
Meakin, N.	14-Nov-11	0.5	Calls with counsel regarding bids and objections.	\$870	\$435.00
Greenberg, M.	14-Nov-11	0.5	Correspondence with counsel regarding settlement negotiations.	\$745	\$372.50
Swetz, M.	14-Nov-11	0.5	Participate in calls with counsel regarding competing sale bids.	\$315	\$157.50
Star, S.	14-Nov-11	0.9	Conference calls with counsel regarding value allocation and sale motion objections.	\$895	\$805.50
Swetz, M.	15-Nov-11	0.2	Participate in call with counsel regarding settlement negotiations.	\$315	\$63.00
Star, S.	15-Nov-11	0.8	Conference call with counsel regarding valuation issues.	\$895	\$716.00
Braun, R.	15-Nov-11	0.8	Participate in call with counsel regarding valuation.	\$730	\$584.00
Korn, G.	15-Nov-11	0.8	Participate in call with counsel regarding valuation.	\$560	\$448.00
Star, S.	15-Nov-11	1.2	Discussions with counsel regarding potential settlement.	\$895	\$1,074.00
Swetz, M.	15-Nov-11	1.5	Participate in call with counsel regarding valuation of Canada and potential litigation strategy.	\$315	\$472.50
Greenberg, M.	15-Nov-11	1.8	Discussions with counsel regarding settlement negotiations, sale process and Canada value.	\$745	\$1,341.00
Swetz, M.	16-Nov-11	0.3	Participate in call with Canadian counsel regarding valuation of Canada.	\$315	\$94.50
Star, S.	16-Nov-11	0.4	Conference call with counsel regarding Canadian registration requirements.	\$895	\$358.00
Greenberg, M.	16-Nov-11	0.4	Discussion with counsel regarding value of Graceway Canada.	\$745	\$298.00
Meakin, N.	16-Nov-11	0.5	Call with counsel regarding valuation and settlement issues.	\$870	\$435.00
Star, S.	16-Nov-11	0.8	Conference call with counsel regarding settlement proposal, status of bids, and depositions.	\$895	\$716.00
Greenberg, M.	16-Nov-11	1.6	Correspondence with counsel regarding settlement negotiations.	\$745	\$1,192.00
Star, S.	17-Nov-11	0.6	Discussions with counsel regarding settlement parameters.	\$895	\$537.00
Greenberg, M.	17-Nov-11	2.0	Meeting with counsel to discuss settlement provisions and creditor recovery analysis.	\$745	\$1,490.00
Swetz, M.	17-Nov-11	2.0	Attend meeting with counsel regarding settlement negotiations.	\$315	\$630.00

**EXHIBIT B**

**GRACEWAY PHARMACEUTICALS, LLC, et al., CASE NO. 11-13036  
DETAILED PROFESSIONAL ACTIVITY BY HOURS AND FEES BY PROJECT CATEGORY  
FOR THE PERIOD NOVEMBER 1, 2011 THROUGH NOVEMBER 30, 2011**

***General Meetings with Committee & Committee Counsel***

<b>Professional</b>	<b>Date</b>	<b>Hours</b>	<b>Activity</b>	<b>Rate</b>	<b>Fees</b>
Greenberg, M.	18-Nov-11	0.2	Correspondence with counsel regarding settlement terms.	\$745	\$149.00
Star, S.	18-Nov-11	0.4	Conference call with counsel regarding settlement parameter.	\$895	\$358.00
Greenberg, M.	18-Nov-11	0.4	Discussion with counsel regarding settlement provisions.	\$745	\$298.00
Swetz, M.	18-Nov-11	0.4	Participate in call with counsel regarding case status and upcoming committee call.	\$315	\$126.00
Meakin, N.	18-Nov-11	0.6	Prepare for call with the Committee regarding proposed settlement.	\$870	\$522.00
Meakin, N.	18-Nov-11	0.9	Conference call with Committee regarding proposed settlement.	\$870	\$783.00
Star, S.	18-Nov-11	0.9	Conference call with Committee regarding proposed settlement.	\$895	\$805.50
Greenberg, M.	18-Nov-11	0.9	Conference call with Committee regarding proposed settlement.	\$745	\$670.50
Star, S.	19-Nov-11	0.2	Discussions with counsel regarding case status and next steps.	\$895	\$179.00
Greenberg, M.	21-Nov-11	0.2	Correspondence with counsel regarding FTI fees and expenses.	\$745	\$149.00
Greenberg, M.	22-Nov-11	0.2	Correspondence with counsel regarding Court hearings on valuation motion and sale motion.	\$745	\$149.00
Greenberg, M.	23-Nov-11	0.2	Correspondence with counsel regarding Canada's October 2011 balance sheet.	\$745	\$149.00
Greenberg, M.	28-Nov-11	0.2	Discussion with counsel regarding 2nd lien lenders.	\$745	\$149.00
Greenberg, M.	29-Nov-11	0.3	Correspondence with counsel regarding FTI fee application.	\$745	\$223.50
<b>Subtotal</b>		<b>47.7</b>			<b>\$35,513.00</b>

***General Meetings with Debtors & Debtors' Professionals***

<b>Professional</b>	<b>Date</b>	<b>Hours</b>	<b>Activity</b>	<b>Rate</b>	<b>Fees</b>
Star, S.	01-Nov-11	0.2	Discussion with Lazard regarding allocation motion.	\$895	\$179.00
Greenberg, M.	03-Nov-11	0.2	Correspondence with A&M regarding weekly cash variance report.	\$745	\$149.00
Greenberg, M.	04-Nov-11	0.2	Correspondence with Debtors regarding Canada product registration and tax analysis.	\$745	\$149.00
Greenberg, M.	04-Nov-11	0.7	Discussion with Debtors regarding asset sale, DIP budget and SOFAs/SOALs.	\$745	\$521.50
Meakin, N.	04-Nov-11	1.0	Prepare for and participate in call with Debtors' Advisors regarding Mezzanine credit agreement.	\$870	\$870.00
Swetz, M.	04-Nov-11	1.0	Prepare for and participate in call with Debtors' Advisors regarding Mezzanine credit agreement.	\$315	\$315.00
Greenberg, M.	08-Nov-11	0.1	Correspondence with A&M regarding transfer pricing.	\$745	\$74.50

**EXHIBIT B**

**GRACEWAY PHARMACEUTICALS, LLC, et al., CASE NO. 11-13036  
DETAILED PROFESSIONAL ACTIVITY BY HOURS AND FEES BY PROJECT CATEGORY  
FOR THE PERIOD NOVEMBER 1, 2011 THROUGH NOVEMBER 30, 2011**

***General Meetings with Debtors & Debtors' Professionals***

<b>Professional</b>	<b>Date</b>	<b>Hours</b>	<b>Activity</b>	<b>Rate</b>	<b>Fees</b>
Greenberg, M.	08-Nov-11	0.3	Discussion with A&M regarding DIP cash budget.	\$745	\$223.50
Greenberg, M.	10-Nov-11	0.3	Correspondence with Debtors regarding case status.	\$745	\$223.50
Swetz, M.	10-Nov-11	0.9	Compile list of questions for Debtors' Advisors related to DIP budget.	\$315	\$283.50
Greenberg, M.	11-Nov-11	0.1	Correspondence with Debtors regarding DIP budget.	\$745	\$74.50
Greenberg, M.	11-Nov-11	0.4	Participate on call with Debtors regarding sale process and Canada value.	\$745	\$298.00
Swetz, M.	11-Nov-11	0.7	Call with Debtors' professionals regarding sale process.	\$315	\$220.50
Star, S.	13-Nov-11	0.3	Telephone call with Lazard regarding bid status.	\$895	\$268.50
Star, S.	14-Nov-11	0.3	Conference call with Debtors regarding qualifying bids.	\$895	\$268.50
Swetz, M.	14-Nov-11	0.5	Participate in call with Debtors' professionals regarding bids and bidders.	\$315	\$157.50
<b>Subtotal</b>		<b>7.2</b>			<b>\$4,276.00</b>

***Meetings with Other Parties***

<b>Professional</b>	<b>Date</b>	<b>Hours</b>	<b>Activity</b>	<b>Rate</b>	<b>Fees</b>
Star, S.	01-Nov-11	0.2	Prepare for meeting with 1st lien lenders regarding settlement.	\$895	\$179.00
Star, S.	02-Nov-11	0.1	Conference call with 2nd lien holder counsel regarding case status.	\$895	\$89.50
Greenberg, M.	02-Nov-11	0.2	Discussion with counsel to the 2nd lien holders regarding case issues.	\$745	\$149.00
Star, S.	02-Nov-11	1.3	Meet with 1st lien lender counsel regarding settlement outline.	\$895	\$1,163.50
Greenberg, M.	02-Nov-11	2.0	Prepare for and participate in meeting with counsel to 1st lien holders regarding settlement negotiations.	\$745	\$1,490.00
Greenberg, M.	03-Nov-11	0.2	Correspondence with counsel to the 1st lien holders regarding FTI retention.	\$745	\$149.00
Star, S.	07-Nov-11	0.4	Conference call with 1st lien lender advisors regarding settlement.	\$895	\$358.00
Swetz, M.	07-Nov-11	0.7	Call with 1st liens regarding settlement discussions.	\$315	\$220.50
Star, S.	11-Nov-11	0.5	Conference call with 1st lien lender regarding settlement proposal.	\$895	\$447.50
Greenberg, M.	11-Nov-11	0.8	Participate on call with counsel to 1st lien lenders regarding settlement negotiations.	\$745	\$596.00
Swetz, M.	11-Nov-11	0.8	Call with 1st liens regarding settlement.	\$315	\$252.00
Greenberg, M.	14-Nov-11	0.4	Participate on call with Debtors, Wachtell and Committee counsel to discuss competing bids.	\$745	\$298.00

**EXHIBIT B**

---

**GRACEWAY PHARMACEUTICALS, LLC, et al., CASE NO. 11-13036  
DETAILED PROFESSIONAL ACTIVITY BY HOURS AND FEES BY PROJECT CATEGORY  
FOR THE PERIOD NOVEMBER 1, 2011 THROUGH NOVEMBER 30, 2011**

---

***Meetings with Other Parties***

<b>Professional</b>	<b>Date</b>	<b>Hours</b>	<b>Activity</b>	<b>Rate</b>	<b>Fees</b>
Greenberg, M.	15-Nov-11	0.4	Participate on call with Lowenstein and counsel to the 1st lien lenders regarding settlement negotiations.	\$745	\$298.00
Star, S.	15-Nov-11	0.5	Conference call with 1st lien lenders regarding potential settlement.	\$895	\$447.50
Swetz, M.	15-Nov-11	0.6	Participate in call with the 1st liens regarding settlement negotiations.	\$315	\$189.00
Greenberg, M.	16-Nov-11	0.3	Discussion with 2nd lien lenders regarding Canada value.	\$745	\$223.50
Star, S.	17-Nov-11	1.1	Discussions with Debtors and 1st lien lenders regarding settlement parameters.	\$895	\$984.50
Greenberg, M.	17-Nov-11	1.3	Meeting with Debtors and counsel to 1st lien lenders regarding settlement negotiations.	\$745	\$968.50
Swetz, M.	17-Nov-11	1.3	Discuss possible settlement with 1st lien's professionals and Debtors' professionals.	\$315	\$409.50
Star, S.	21-Nov-11	0.5	Conference call with 2nd lien holder regarding case status.	\$895	\$447.50
Greenberg, M.	23-Nov-11	0.1	Correspondence with 2nd lien holders regarding settlement with 1st lien holders.	\$745	\$74.50
Star, S.	28-Nov-11	0.1	Review 2nd lien correspondence.	\$895	\$89.50
<b>Subtotal</b>		<b>13.8</b>			<b>\$9,524.00</b>

***POR & DS - Analysis, Negotiation and Formulation***

<b>Professional</b>	<b>Date</b>	<b>Hours</b>	<b>Activity</b>	<b>Rate</b>	<b>Fees</b>
Swetz, M.	01-Nov-11	1.8	Analyze possible settlement parameters and matters related to the upcoming filing of objection to allocation motion.	\$315	\$567.00
Star, S.	07-Nov-11	0.6	Update creditor recovery analysis.	\$895	\$537.00
Star, S.	11-Nov-11	1.9	Develop settlement proposal modifications.	\$895	\$1,700.50
Star, S.	14-Nov-11	0.6	Review economic analysis for settlement proposal.	\$895	\$537.00
Swetz, M.	15-Nov-11	1.6	Analyze possible settlement terms and potential impact to unsecured creditors.	\$315	\$504.00
Greenberg, M.	15-Nov-11	2.1	Revise settlement structure for negotiations with counsel to the 1st lien lenders.	\$745	\$1,564.50
Star, S.	16-Nov-11	0.5	Develop settlement proposal.	\$895	\$447.50
Greenberg, M.	16-Nov-11	3.2	Prepare analysis supporting settlement negotiations with 1st lien lenders.	\$745	\$2,384.00
Star, S.	18-Nov-11	0.4	Review revised creditor recovery analysis.	\$895	\$358.00
Greenberg, M.	18-Nov-11	2.6	Prepare creditor recovery analysis for distribution to the UCC.	\$745	\$1,937.00

## EXHIBIT B

---

**GRACEWAY PHARMACEUTICALS, LLC, et al., CASE NO. 11-13036  
DETAILED PROFESSIONAL ACTIVITY BY HOURS AND FEES BY PROJECT CATEGORY  
FOR THE PERIOD NOVEMBER 1, 2011 THROUGH NOVEMBER 30, 2011**

---

### *POR & DS - Analysis, Negotiation and Formulation*

<b>Professional</b>	<b>Date</b>	<b>Hours</b>	<b>Activity</b>	<b>Rate</b>	<b>Fees</b>
Star, S.	19-Nov-11	0.2	Review settlement documentation.	\$895	\$179.00
<b>Subtotal</b>		<b>15.5</b>			<b>\$10,715.50</b>

### *Potential Avoidance Actions & Litigation Matters*

<b>Professional</b>	<b>Date</b>	<b>Hours</b>	<b>Activity</b>	<b>Rate</b>	<b>Fees</b>
Greenberg, M.	01-Nov-11	0.6	Review schedule of payments made within 90 days prior to filing.	\$745	\$447.00
Swetz, M.	01-Nov-11	0.9	Prepare 90 day payment summary.	\$315	\$283.50
Swetz, M.	01-Nov-11	2.1	Review payments made in 90 days before bankruptcy filing.	\$315	\$661.50
Swetz, M.	03-Nov-11	1.2	Review of information regarding tax distributions and 90 day payments.	\$315	\$378.00
Greenberg, M.	04-Nov-11	0.4	Review potential preference payments.	\$745	\$298.00
<b>Subtotal</b>		<b>5.2</b>			<b>\$2,068.00</b>

### *Preparation of Fee Application*

<b>Professional</b>	<b>Date</b>	<b>Hours</b>	<b>Activity</b>	<b>Rate</b>	<b>Fees</b>
Stewart, P.	14-Nov-11	0.3	Communications with M. Greenberg (FTI) regarding fee application process.	\$210	\$63.00
Stewart, P.	14-Nov-11	1.5	Review interim fee procedures and retention documents.	\$210	\$315.00
Stewart, P.	14-Nov-11	2.8	Review and revise October fee application.	\$210	\$588.00
Stewart, P.	15-Nov-11	2.6	Prepare exhibits for the October fee application.	\$210	\$546.00
Stewart, P.	15-Nov-11	2.8	Prepare preliminary draft of the October fee application pleading.	\$210	\$588.00
Stewart, P.	15-Nov-11	2.9	Review and revise time descriptions based upon the requirements set forth in the Local Rules of the Bankruptcy Court and the U.S. Trustee guidelines.	\$210	\$609.00
Stewart, P.	16-Nov-11	2.9	Review and revise the October fee application.	\$210	\$609.00
Stewart, P.	18-Nov-11	0.8	Review and revise draft of the monthly fee application.	\$210	\$168.00
Stewart, P.	21-Nov-11	0.5	Review and revise the October fee application.	\$210	\$105.00
Stewart, P.	22-Nov-11	1.8	Review and revise October fee application pleading.	\$210	\$378.00
Stewart, P.	22-Nov-11	2.5	Review and revise October fee application exhibits.	\$210	\$525.00
Stewart, P.	23-Nov-11	2.3	Preparation of the revised October fee application.	\$210	\$483.00

## EXHIBIT B

---

**GRACEWAY PHARMACEUTICALS, LLC, et al., CASE NO. 11-13036  
DETAILED PROFESSIONAL ACTIVITY BY HOURS AND FEES BY PROJECT CATEGORY  
FOR THE PERIOD NOVEMBER 1, 2011 THROUGH NOVEMBER 30, 2011**

---

### *Preparation of Fee Application*

<b>Professional</b>	<b>Date</b>	<b>Hours</b>	<b>Activity</b>	<b>Rate</b>	<b>Fees</b>
Greenberg, M.	23-Nov-11	2.4	Review FTI's monthly fee application.	\$745	\$1,788.00
Star, S.	24-Nov-11	0.8	Review October fee application.	\$895	\$716.00
Stewart, P.	29-Nov-11	0.9	Review and revise the October fee application.	\$210	\$189.00
Stewart, P.	29-Nov-11	2.4	Finalize October fee application and invoice.	\$210	\$504.00
<b>Subtotal</b>		<b>30.2</b>			<b>\$8,174.00</b>

### *Prepare for and Attend Court Hearings*

<b>Professional</b>	<b>Date</b>	<b>Hours</b>	<b>Activity</b>	<b>Rate</b>	<b>Fees</b>
Star, S.	07-Nov-11	0.3	Attend court hearing regarding DIP financing and professional retentions.	\$895	\$268.50
<b>Subtotal</b>		<b>0.3</b>			<b>\$268.50</b>

### *Travel Time*

<b>Professional</b>	<b>Date</b>	<b>Hours</b>	<b>Activity</b>	<b>Rate</b>	<b>Fees</b>
Star, S.	07-Nov-11	1.0	Non-billable travel time to / from court hearing; New York, NY to Wilmington, DE (1/2 total time incurred). *** NO CHARGE ***	\$895	\$0.00
Star, S.	07-Nov-11	1.0	Travel time to / from court hearing; New York, NY to Wilmington, DE (charged at 1/2 total time incurred).	\$895	\$895.00
<b>Subtotal</b>		<b>2.0</b>			<b>\$895.00</b>

### *Valuation and Related Matters*

<b>Professional</b>	<b>Date</b>	<b>Hours</b>	<b>Activity</b>	<b>Rate</b>	<b>Fees</b>
Braun, R.	01-Nov-11	1.5	Review and analyze Canada valuation.	\$730	\$1,095.00
Greenberg, M.	02-Nov-11	0.6	Review license agreement between Pharma and Canada.	\$745	\$447.00
Star, S.	03-Nov-11	0.5	Review Canada valuation issues.	\$895	\$447.50
Meakin, N.	03-Nov-11	0.6	Review valuation updates.	\$870	\$522.00
Greenberg, M.	03-Nov-11	0.6	Review Canada license agreement and summarize terms.	\$745	\$447.00
Braun, R.	03-Nov-11	2.0	Review and analyze Canada valuation.	\$730	\$1,460.00
Braun, R.	07-Nov-11	1.7	Review and analyze Canada valuation.	\$730	\$1,241.00



## EXHIBIT B

---

**GRACEWAY PHARMACEUTICALS, LLC, et al., CASE NO. 11-13036  
DETAILED PROFESSIONAL ACTIVITY BY HOURS AND FEES BY PROJECT CATEGORY  
FOR THE PERIOD NOVEMBER 1, 2011 THROUGH NOVEMBER 30, 2011**

---

### *Valuation and Related Matters*

<b>Professional</b>	<b>Date</b>	<b>Hours</b>	<b>Activity</b>	<b>Rate</b>	<b>Fees</b>
Greenberg, M.	08-Nov-11	1.0	Review audited financial statements.	\$745	\$745.00
Greenberg, M.	08-Nov-11	1.3	Review data room documents pertaining to Canada value.	\$745	\$968.50
Swetz, M.	08-Nov-11	1.9	Prepare schedule of Canadian value under various scenarios.	\$315	\$598.50
Swetz, M.	08-Nov-11	2.2	Prepare valuation analysis.	\$315	\$693.00
Swetz, M.	08-Nov-11	2.8	Analyze IPL agreement for preparation of valuation analysis.	\$315	\$882.00
Star, S.	09-Nov-11	0.4	Review FTI's Canada allocation analysis.	\$895	\$358.00
Braun, R.	09-Nov-11	0.5	Review and analyze Canada valuation.	\$730	\$365.00
Swetz, M.	09-Nov-11	0.8	Review draft of counsel's valuation objection and prepare suggested revisions.	\$315	\$252.00
Greenberg, M.	09-Nov-11	1.8	Prepare preliminary analysis of Canada equity value.	\$745	\$1,341.00
Greenberg, M.	09-Nov-11	2.1	Research license agreements between US and Canada, and develop comparison analysis.	\$745	\$1,564.50
Swetz, M.	09-Nov-11	3.6	Prepare updates to valuation of Canada for settlement purposes.	\$315	\$1,134.00
Star, S.	10-Nov-11	0.6	Review Canada value allocation calculations.	\$895	\$537.00
Greenberg, M.	10-Nov-11	0.7	Prepare preliminary analysis of Canada equity value.	\$745	\$521.50
Swetz, M.	10-Nov-11	1.4	Review IPL license agreement regarding Canadian value.	\$315	\$441.00
Braun, R.	10-Nov-11	1.5	Review and analyze Canada valuation.	\$730	\$1,095.00
Greenberg, M.	10-Nov-11	3.0	Research license agreements between US and Canada, and develop comparison analysis.	\$745	\$2,235.00
Star, S.	11-Nov-11	0.5	Review counsel memo regarding value of Canadian permits and authorizations.	\$895	\$447.50
Braun, R.	11-Nov-11	1.6	Review and analyze Canada valuation.	\$730	\$1,168.00
Swetz, M.	11-Nov-11	2.1	Update valuation of Canada incorporating various scenarios.	\$315	\$661.50
Swetz, M.	11-Nov-11	2.3	Prepare analysis of Canada valuation for purposes of further settlement discussions.	\$315	\$724.50
Greenberg, M.	11-Nov-11	4.4	Prepare analysis of Graceway Canada equity value.	\$745	\$3,278.00
Star, S.	12-Nov-11	0.6	Review value allocation objection.	\$895	\$537.00
Greenberg, M.	12-Nov-11	2.2	Prepare valuation analysis for settlement negotiations.	\$745	\$1,639.00
Star, S.	13-Nov-11	0.5	Develop exhibit for value allocation objection.	\$895	\$447.50
Swetz, M.	13-Nov-11	0.9	Review competing bid with regard to impact on valuation of Canada.	\$315	\$283.50
Greenberg, M.	13-Nov-11	1.4	Prepare valuation analysis for settlement negotiations.	\$745	\$1,043.00

**EXHIBIT B**

---

**GRACEWAY PHARMACEUTICALS, LLC, et al., CASE NO. 11-13036  
DETAILED PROFESSIONAL ACTIVITY BY HOURS AND FEES BY PROJECT CATEGORY  
FOR THE PERIOD NOVEMBER 1, 2011 THROUGH NOVEMBER 30, 2011**

---

*Valuation and Related Matters*

<b>Professional</b>	<b>Date</b>	<b>Hours</b>	<b>Activity</b>	<b>Rate</b>	<b>Fees</b>
Greenberg, M.	13-Nov-11	2.3	Review drafts of valuation motion and sale motion objections and provide comments to counsel.	\$745	\$1,713.50
Star, S.	14-Nov-11	0.7	Review revised value allocation objection.	\$895	\$626.50
Greenberg, M.	14-Nov-11	0.9	Review drafts of valuation motion and sale motion objections and provide comments to counsel.	\$745	\$670.50
Braun, R.	14-Nov-11	1.7	Review and revise merged and acquired company analysis.	\$730	\$1,241.00
Greenberg, M.	14-Nov-11	2.1	Prepare valuation analysis for settlement negotiations.	\$745	\$1,564.50
Braun, R.	14-Nov-11	2.7	Prepare valuation analysis.	\$730	\$1,971.00
Swetz, M.	14-Nov-11	3.0	Prepare schedule of value for Canada incorporating new bids.	\$315	\$945.00
Star, S.	15-Nov-11	1.2	Review valuation issues.	\$895	\$1,074.00
Braun, R.	15-Nov-11	2.5	Review and revise guideline publicly traded company analysis.	\$730	\$1,825.00
Greenberg, M.	15-Nov-11	2.7	Analyze Canada value.	\$745	\$2,011.50
Korn, G.	15-Nov-11	2.8	Perform merged and acquired company analysis related to the valuation.	\$560	\$1,568.00
Korn, G.	15-Nov-11	2.9	Perform guideline publicly traded company analysis related to the valuation.	\$560	\$1,624.00
Yozzo, J.	16-Nov-11	0.5	Obtain historical financial and narrative downloads for three drug companies.	\$545	\$272.50
Star, S.	16-Nov-11	0.6	Review draft exhibits to declaration.	\$895	\$537.00
Star, S.	16-Nov-11	0.6	Prepare for depositions in connection with allocation hearing.	\$895	\$537.00
Swetz, M.	16-Nov-11	1.6	Review projections and financial data for consideration of value of Canada.	\$315	\$504.00
Korn, G.	16-Nov-11	1.8	Perform guideline publicly traded company analysis related to the valuation.	\$560	\$1,008.00
Swetz, M.	16-Nov-11	2.2	Prepare strategic buyer list for possible comparable companies for valuation analysis.	\$315	\$693.00
Korn, G.	16-Nov-11	2.5	Perform review of adjustments to normalize the trailing twelve month income statement.	\$560	\$1,400.00
Greenberg, M.	16-Nov-11	2.8	Analyze Debtors' historical financial statements and 5-year forecast.	\$745	\$2,086.00
Korn, G.	16-Nov-11	2.8	Prepare valuation analysis.	\$560	\$1,568.00
Korn, G.	16-Nov-11	2.9	Perform financial modeling related to the presentation of our valuation analysis.	\$560	\$1,624.00
Braun, R.	16-Nov-11	4.1	Prepare DCF valuation model.	\$730	\$2,993.00

**EXHIBIT B**

---

**GRACEWAY PHARMACEUTICALS, LLC, et al., CASE NO. 11-13036  
DETAILED PROFESSIONAL ACTIVITY BY HOURS AND FEES BY PROJECT CATEGORY  
FOR THE PERIOD NOVEMBER 1, 2011 THROUGH NOVEMBER 30, 2011**

---

***Valuation and Related Matters***

<b>Professional</b>	<b>Date</b>	<b>Hours</b>	<b>Activity</b>	<b>Rate</b>	<b>Fees</b>
Braun, R.	17-Nov-11	0.7	Review footnotes of 10-K filings for the publicly traded companies used as comparable companies used in our analysis in search of a breakout of corporate overhead charges.	\$730	\$511.00
Korn, G.	17-Nov-11	1.1	Perform review of the footnotes of 10-K filings for the publicly traded companies used as comparable companies used in our analysis in search of a breakout of corporate overhead charges.	\$560	\$616.00
Swetz, M.	17-Nov-11	1.7	Review additional possible comps for valuation analysis.	\$315	\$535.50
Star, S.	17-Nov-11	1.8	Prepare deposition exhibits.	\$895	\$1,611.00
Braun, R.	17-Nov-11	2.1	Review spreadsheet to display the product revenue segment information of each guideline publicly traded company used in our valuation analysis.	\$730	\$1,533.00
Swetz, M.	17-Nov-11	2.1	Review and analyze valuation exhibits under different sets of assumptions.	\$315	\$661.50
Braun, R.	17-Nov-11	2.2	Review geographic and segment information of target companies used in the merged and acquired company analysis.	\$730	\$1,606.00
Korn, G.	17-Nov-11	2.4	Create a spreadsheet to display the product revenue segment information of each guideline publicly traded company used in our valuation analysis.	\$560	\$1,344.00
Korn, G.	17-Nov-11	2.6	Perform search for geographic and segment information of target companies used in our merged and acquired company analysis.	\$560	\$1,456.00
Korn, G.	17-Nov-11	3.0	Create a spreadsheet to display the geographic segment information of each guideline publicly traded company used in our valuation analysis.	\$560	\$1,680.00
Braun, R.	18-Nov-11	2.9	Prepare valuation analysis.	\$730	\$2,117.00
Korn, G.	18-Nov-11	2.9	Compile information related to the valuation analysis.	\$560	\$1,624.00
Greenberg, M.	23-Nov-11	0.6	Review October balance sheet results for Canada and prepare comparison to September.	\$745	\$447.00
Greenberg, M.	23-Nov-11	2.2	Review Canadian Receiver's second publicly filed report.	\$745	\$1,639.00
Greenberg, M.	25-Nov-11	0.3	Review Canada's September 2011 financial statements.	\$745	\$223.50
<b>Subtotal</b>		<b>126.1</b>			<b>\$77,281.50</b>
<b>Grand Total</b>		<b>335.2</b>			<b>\$196,238.50</b>

**EXHIBIT C**

---

**GRACEWAY PHARMACEUTICALS, LLC, et al., CASE NO. 11-13036  
DETAILED EXPENSES BY CATEGORY  
FOR THE PERIOD NOVEMBER 1, 2011 THROUGH NOVEMBER 30, 2011**

---

*Research*

<b>Professional/Service</b>	<b>Date</b>	<b>Expense</b>	<b>Expense Description</b>
Korn, G.	11/1/2011	\$228.86	Third party (Alacra Inc.) research charges related to valuation.
		<b>\$228.86</b>	

*Transportation*

<b>Professional/Service</b>	<b>Date</b>	<b>Expense</b>	<b>Expense Description</b>
Star, S.	11/4/2011	\$315.00	Round trip train fare; New York, NY to Wilmington, DE to attend court hearing.
		<b>\$315.00</b>	

*Grand Total* **\$543.86**